2016 autumn ebm free excerpt by BIOCOM Interrelations GmbH

ISSN 2364-2351 | A 60711 |

Life Sciences and Industry Magazine Autumn Edition 2016 | Volume 15 | 20 €

Interview EMA‘s Senior Medical Officer Hans-Georg Eichler talks about the agency’s Adaptive Pathways pilot programme.

T P R E C EE EX

Sepsis The race against time

Exosomes

Longevity

Bioeconomy

CROs & CMOs

Nanovesicles take personalised medicine to the next level

Endogenous biomarker points to an increased life expectancy

Can carbon dioxide emissions act as a feedstock for industry?

Specialists and generalists in the expanding outsourcing market

45% cashback for clinical trials

in Adelaide Forty-five per cent of R&D costs will be reimbursed in

cash to eligible companies with an aggregated annual turnover of less than A$20 million (approx. US$15 million). Costs covered include clinical trials, analytics, study drug manufacture, and other R&D. Adelaide also delivers clinical trials ethics approval in an average of just six weeks, saving six to nine months compared to trials in the US or Europe.

CONTENTS

European Biotechnology | Autumn Edition | Vol. 15 | 2016

FREE EXCERPT

coveR stoRy

insight euRope

Regional news

68 Northern Europe: Sweden, Denmark, Finland and Norway

Pesticide and biocide producers scrutinise laws drafted by the European Commission to ban harmful endocrine disruptors from EU markets EMA tables new pharmaco vigilance rules for biologics; GM soy flooding into the EU; Experts call for more international bio ecomy collaboration

10 Adaptive Pathways: EMA faces criticism of HTA organisations after publication of final report 12 Experts recommend automatically interchanging originators with biosimilars; Heard in Brussels: Into the Brexshit

Sepsis: Targeting a silent killer For over three decades, attempts among drug developers to target the inflamma tory pathways and symptoms of sepsis have been fruitless. New rapid diagnos tics, rigourous patient stratification and drugs with novel modes of action are now on the horizon for treating the most costly cause of death in the industrial ised world. Biotechs are pushing new ideas towards clinical testing, but there just isn’t enough funding available in the EU. Will US investors again pick up European innovation on the cheap?

economy

70 Western Europe: France, Belgium, The Netherlands and the UK 72 Central Europe: Germany, Switzerland and Austria 76 Southern Europe: Italy, Spain, Portugal and Slovenia 78 Eastern Europe: Hungary, Poland, Czech Republic, Estonia and Slovakia

science & technology 86 Mortal span: study on centenarians links microcirculation biomarker to longevity

23 EMA News 24 Cancer immune therapies: Novartis spins out CAR-T cell business; IP Flash 25 Update on clinical trials 28 Interview: HansGeorg Eichler, European Medicines Agency, London, on Adaptive Pathways

88 Swedish researchers identify inflammation switch; Making marine plastics a biofuel resource; Using autoantibodies to target autoimmune diseases; How calorie restriction can improve DNA repair

seRvice 44 Biopeople

33 Analyst commentary 34 Euro Biotech Stocks

91 News from partner associations: SBA, BIO Deutschland, DIA, EBN

36 Startup story: Glycemicon AG, Brugg, Switzerland

96 Events 97 Company index/Product 98 Encore

IMPRINT European Biotechnology (ISSN 23642351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D10785 Berlin, Germany, Tel.: +49302649210, Fax: +493026492111, Email: service@eurobiotechnews.eu, Internet: www.eurobiotechnews.eu; Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Uta Mommert, Dr. Martin Laqua, Julie Colthorpe, Dr. Bernd Kaltwaßer, Sascha Karberg; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution: Marcus Laschke, +49-30-2649-2148; Graphic Design: Michaela Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 80.00, Students € 40.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of prepaid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All mate rial published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: © YinYang/istockphoto.com. ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

Picture: YinYang/istockphoto.com

CONTENTS

European Biotechnology | Autumn Edition | Vol. 15 | 2016

FREE EXCERPT

economy

BiosimilaRs

editoRial

What is reality?

The CO2 opportunity Although most people still view car bon dioxide (CO2) as a climate killer, industry is beginning to realise that CO2 could actually provide an abundant, lowcost feedstock for carbonbased processes. A number of Carbon Capture and Utilisation (CCU) schemes are evaluating the many different pathways that could play a role in the field in the future.

Extracellular vesicles: Better than stem cells? Disregarded for decades, exosomes are now understood to be a key element in communication between cells. Discov eries around the nanosized bubbles are revolutionising not only the field of diagnostics. With their ability to mimic stem cells, EVs could also help open the doors to novel therapeutic concepts.

SPECIAL Pictures: Qiagen (top), Photobank/fotolia.com (middle), cassis/fotolia.com (bottom)

CMOs & CROs 47 Intro: Damned to outsource 50 Update for production in Pichia 52 Ethics approval in just six weeks in Adelaide 56 CHOvolution – an innovative development platform 58 The future of the biotech outsourcing market 60 Preventing resistance sequences in AAV vector systems 62 User-centred solutions for optimising clinical trials management 66 The many faces of fucose

Anonymised real-world data that complement data from randomised clinical trails (RCTs) can help companies investigate how their medicines are being used in clinical practice. Boehringer Ingelheim used them in a post-marketing study on patients who receive its blood thinner Pradaxa (dabigatran) antidote Praxbind (idarucizumab). While at the end of August, Takeda started the ever-largest observational study (5,000 patients) to track patterns in disease presentation, patient characteristics, treatment and outcomes in patients with multiple myeloma. The correlations found are aimed at informing treatment decisions, selecting appropriate patient groups, and evaluating patient benefit. The regulatory consequence of this switch to Big Data collection from medical records, however, may end in a mix of costly RCTs and real-world data in the drug authorisation process (see p. 28). Real-world data could also inform patient stratification in developing new therapies for sepsis, the world's most costly medical complication (see p. 14). And data collected by companies is even helping to establish links between genes, habits and longevity (see p. 86). There's still a major open question, though. Will data-driven correlation sciences – and thus computers – one day be able to describe biological reality, and complement experiencedriven medical know-how?

Thomas Gabrielczyk EditorinChief

InsIght EuropE

European Biotechnology | Autumn Edition | Vol. 15 | 2016

FREE EXCERPT

Signal from Australia Biosimilar suBstitution In Europe,

the Finnish, german, Dutch and Irish Medicines Agencies have clearly taken a stance on the interchangeability of bio similars under supervision of physicians when welldocumented. however, nei ther a member state agency nor the Euro pean Medicines Agency (EMA) itself has ever backed automatic subsitution at the pharmacy level. Although “the theoreti cal basis for adverse effects is weak”, ac cording to niklas Ekman from the Finn ish Medicines Agency (FIMEA), and albeit “clinical crossover studies conducted [so far] have given no evidence of adverse effects due to a switch from a reference product to a biosimilar”, Europeans tend to be cautious. Discussions on the topic at the interna tional level are now set to be revivified by a recent decision of Australia’s phar maceutical Benefits Advisory Committee (PBAC). In August, one month after the therapeutic goods Administation (tgA) granted market authorisation to samsung Bioepis’ biosimilar Brenzys (etanercept), the experts gave pharmacists the authori ty to substitute the copycat biologic (mar keted by Merck & Co) for its reference product, Enbrel (etanercept), marketed by Amgen and Pfizer. The PBAC said Brenzys “could be marked as equivalent” to Enbrel on the Australian Pharmaceutical Benefits scheme (pBs), allowing the biosimilar tnF inhibitor’s substitution to treat all in dications for which both drugs are ap proved: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloar thritis. PBAC noted that a prescriber may choose to not permit substitution of the biosimilar. the biosimilar was first approved in south Korea while Eu authorisation for “Benepali“ was given by the EMA this February. 

Heard in Brussels In the Brexshit collaboration is a viBrussels Well, those tal part of that – espebloody idiots in the cially for UK universiUK managed to do it ties, which dominate – talk themselves from EU programmes, and decades of hysteria the UK will be walkabout straight bananas ing away from that (entirely fabricated by if freedom of moveone B Johnson during ment is compromised. his time as a journalOnce you weaken the ist in Brussels) into acinnovation base, the tually voting to leave. industry that grows The UK can now befrom it will follow, and stride the world once it is not just about the more, free from the money, it is about colshackles of EU tyranClaire skentelBery laboration and abiliny, ready to reassume Secretary General of the Euroty to lead internationthe economic, social pean Biotechnology Network al research. The UK and moral magnifiwill be unable to attract great scientists cence of its colonial heyday. Look out if their career path is limited, regardless Zimbabwe, hope you kept all those Rhoof domestic funding levels. desia passports and hey US, they are he impact on UK science has already expecting you back in the same condistarted. Scientists for EU has recordtion in which they left you. Form an ored more than 40 cases of UK univerderly queue. sity researchers being asked to leave project consortia for H2020 deadlines Imbeciles after June 23, and we can expect a big drop in UK presence in projects, parOf course this is great for science, as Britticularly as coordinators. In big compaain was ACE at that – no need for any nies, planned posts are being relocated kind of plan there. As I was repeatedinto the wider EU, while scientists from ly told by Brexit campaigners, science mainland Europe are declining job ofand scientific collaboration just happen, fers. The EMA will pack its bags in Lonthey don’t need any kind of funding and don and take with it the skilled comcommon framework to help it along. mercial regulatory community that has The UK certainly doesn’t need any exgrown up around it, while the planned perts, as the whole country was told by EU patent court won’t even start. Finalthe Justice Secretary Michael Gove – so ly, structural funds to help regions deall those pesky Nobel prize winners who velop better scientific capability are alsaid Brexit was a stupid idea can just go ready on hold, even before Article 50 back to looking pretty in a lab coat. is triggered. Suck it up Wales – you get what you voted for. Knuckleheads National excellence is an international game, especially in science. Being The UK currently has a strong sector, but proudly independent/insanely deludfor how much longer, given its 1.7% GDP ed (delete as applicable) comes with a spent on R&D (OECD) is lower than the price and the UK does not have the curEU average, bottom of the G7 and far berency to pay the bill.  hind Germany’s 2.8%? EU funding and

Picture: EBN

SepSiS

european Biotechnology | Autumn edition | Vol. 15 | 2016

FREE EXCERPT

Fooling a silent killer Although policymakers have grown loud about antibiotic resistance – which currently kills about 80,000 people per year globally – they mostly ignore sepsis, which claims ten times as many lives. Despite a significant lack of funding for clinical validation, a new generation of diagnostics and therapeutics is in the pipeline that promises targeted patient selection and better outcomes within the next five years.

SepSiS

Pictures: Dr_Kateryna/fotolia.com (left); Jena University Hospital (right)

hen he was born in 1947, nobody could have predicted that the baby born Cassius Clay would become a three-time boxing world heavyweight champion who would win 56 out of 61 matchups, with 37 knockouts. Last spring, Muhammed Ali – a.k.a. “The Greatest” – lost his final fight. The 74-year-old champion, who suffered from parkinson’s disease in later life, died of septic shock at a hospital in the southwestern US city of phoenix. Sepsis is a life-threatening condition that arises when the body’s response to an infection injures its own tissues and organs. it occurs when the body’s local response to an invasion and microbial toxins – in Ali’s case a respiratory infection – expands to the entire body. The condition is a ruthless, silent killer. Somewhere in the world, someone dies of it around every four seconds. in the nations of the South, collateral damage caused by the systemic infection is greatest. every year, six million babies and 100,000 mothers from the poorest part of the world die from sepsis, in the throes of symptoms that include uncontrolled inflammation, vascular leakage, severe hypotension, organ damage and shock. it’s the most common cause of death by infection there. But even in countries with well-equipped iCUs such as the US, about 260,000 of the 1.1 million patients who are diagnosed with sepsis each year die. With annual costs estimated at US$24bn in 2013 – US$3.4bn more that two years before – sepsis therapy and post-treatment eat up a whopping 7% of the US healthcare budget. in europe, which counts 1.2 million sepsis in-

fections each year, the situation is no better. Around 40% of all iCU patients die from the amok immune response. Due to its complex etiology, there is still not a single drug approved for market that could stop the condition’s inexorable march. Since the 1980s, drug developers have carried out more than 60 late-stage clinical trails with sepsis drugs that target the molecules triggering host response, but most failed to improve pa-

tient outcomes (see graphic p. 16, table p. 18). That’s why doctors at iCUs focus on stopping the consequences of sepsis. Standard of care includes:

›› surgical removal of the centre of infection

›› antimicrobial/antibiotic therapy ›› stabilisation of blood pressure, circulation and organ perfusion

›› support of organ function.

New tests and biomarkers for early diagnosis

KonRad ReinhaRt Founding President, Global Sepsis alliance

What measure is most key in your opinion to prevent deaths from sepsis?

Time. Every hour it remains undiagnosed increases the probability it will kill a patient. So the faster you act, the more probable a good outcome. Currently, there is a range of diagnostic biomarkers in clinical development that could trigger a revolution in treatment by accelerating pathogen detection and diagnosis of sepsis and organ failure.

But there is some reason for optimism, according to Konrad Reinhart, the founding president of the Global Sepsis Alliance and author of 800 scientific papers on the subject. He believes that at least a quarter of all sepsis deaths in the industrialised world are preventable if sepsis can only be diagnosed and treated earlier or prevented. “Sepsis is the most common preventable cause of death,” he told Euro pEan BiotEchnology. “every hour sepsis is not diagnosed increases the probability it will kill the patient by 2%. Recognising the early signs of sepsis is therefore crucial. Sepsis is an emergency situation: the faster you act, the better the chance for a good outcome.” According to the expert, there are now tests on the horizon that could identify the underlying (mostly bacterial) infection and pathogen within 2-6 hours. Today’s gold standard – aerobic and anaerobic blood culture followed by bacterial culture for… ›› Read the full story in the printed issue.

life science-

EXPERTE

und E-Commerce-Marktführer Die führenden Life Science-Unternehmen Merck Millipore + Sigma-Aldrich haben sich zusammengeschlossen, und mit unserer führenden E-CommercePlattform und unserem weltweiten Vertriebsnetz können wir auch Ihr Business vereinfachen – damit Sie sich Ihrer Aufgabe widmen können, die größten Herausforderungen von Life Science zu meistern.

Das Life Science-Geschäft von Merck verfügt über: • Ein erweitertes globales Netzwerk, das mehr als 66 Länder einschließt • Eine erstklassige E-Commerce-Plattform für unkomplizierte Bestellungen • Ein großes Portfolio mit mehr als 300.000 Produkten Mit vereinten Kräften werden wir Wissen und Know-how und beste Ressourcen bereitstellen. Weitere Informationen unter merckgroup.com/life-science Der Life Science-Geschäftszweig von Merck tritt in den USA und Kanada als MilliporeSigma auf. Merck, Merck Millipore, MilliporeSigma und das bunte M sind Marken der Merck KGaA und ihrer Tochterunternehmen. Sigma-Aldrich ist eine Marke der Sigma-Aldrich Co. LLC und ihrer Tochterunternehmen. Copyright © 2016 Merck KGaA. Alle Rechte vorbehalten.

BioEconomy

European Biotechnology | Autumn Edition | Vol. 15 | 2016

FREE EXCERPT

Climate danger – and opportunity Perceptions of CO2 have undergone a remarkable change in the past few years. Although most people still view the gas as a climate killer, Carbon Capture and Storage (CCS) recently began to appear to provide viable options for disposal. Now industry is beginning to realise that CO2 could provide an abundant, low-cost feedstock for carbon-based processes as well. A number of Carbon Capture and Utilisation (CCU) schemes are evaluating the biological, chemical and physical pathways that could play a role in the field. Carbon Capture and utilisation

›› Read the full story in the printed issue.

Picture: Photobank/fotolia.com

DiAgnostics & thEr Apy

European Biotechnology | Autumn Edition | Vol. 15 | 2016

FREE EXCERPT

Extracellular – and extraordinary Even though they’re in the nanometer range, extracellular vesicles (EVs) could start to make it big in the next few years. Long ignored as “cell debris”, the tiny bubbles have now been recognized as a key component in the complex communication between cells. EVs carry genet ic material and proteins throughout the fluids in the body, and have biological properties com parable to stem cells – but apparently safer. They could serve as vaccines, carry cancer immuno therapies, or play a role in regenerative medicine. Ideas and potential markets are growing fast. ExosomEs

›› Read the full story in the printed issue.

Picture: Qiagen

european Biotechnology | autumn edition | Vol. 15 | 2016

Company index FREE EXCERPT

aB Science Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 abbott diagnostics (GeR) . . . . . . . . . . . . . . . . . . . . . . . . 18 abbVie inc. (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 abivax aB (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 ablynx nV (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 acumen Research Laboratories (SG) . . . . . . . . . . . . . . . . 18 adaptimmune Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . . 23 adrenomed aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . 17, 22 advanced Biotherapeutics Consulting SaR . . . . . . . . . . . 23 affymetrix Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 agennix aG (GeR/USa) . . . . . . . . . . . . . . . . . . . . . . . . . 18 akari Therapeutics plc (UK) . . . . . . . . . . . . . . . . . . . . . . 23 alcon Corp. (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 alexion europe SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 23 alga pangea GmbH (aT) . . . . . . . . . . . . . . . . . . . . . . . . . 74 alligator Bioscience aB (Se) . . . . . . . . . . . . . . . . . . . . . . 69 alteco medical aB (Se) . . . . . . . . . . . . . . . . . . . . . . . . . . 22 am-pharma B.V. (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 amgen inc. (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 analytiCon discovery GmbH (GeR) . . . . . . . . . . . . . . . . 72 araclon Biotech (eS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 areva med (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 asahi Kasei pharma (Jp) . . . . . . . . . . . . . . . . . . . . . . . . . 20 astraZeneca aB (Se/UK) . . . . . . . . . . . . . . . . . . . . . . . . . 25 athena Vision Ltd (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . 23 axon neuroscience Se (Cy) . . . . . . . . . . . . . . . . . . . . . . 79 Batavia Biosciences (nL) . . . . . . . . . . . . . . . . . . . . . 49, 58 Baxalta (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23, 26 Bayer aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 44 Bayer Healthcare aG (GeR) . . . . . . . . . . . . . . . . . . . . . . 74 Bd Life Sciences (USa) . . . . . . . . . . . . . . . . . . . . . . . . . 18 Bio-Rad Laboratories (USa) . . . . . . . . . . . . . . . . . . . . . . 44 Biocartis Sa (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Bioceros Holding nV (nL) . . . . . . . . . . . . . . . . . . . . . . . 78 BioCom aG (GeR) . . . . . . . . . . . . . . . . . . . 21, 27, 31, 90 Biogen idec (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 44 BioGenes GmbH (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . 54 Biomerieux (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Biotest aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Boehmert & Boehmert (GeR) . . . . . . . . . . . . . . . . . . 24, 89 Brahms aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Brain aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Bristol myers Squibb (USa). . . . . . . . . . . . . . . . . . . . 25, 70 CandoR Bioscience GmbH (GeR) . . . . . . . . . . . . . . . . 97 Cellectis Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Celonic aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . 51, 56 Celyad Sa (B) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Chemops menges (Si) . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Cinfa Biotech SL (eS/GeR). . . . . . . . . . . . . . . . . . . . . . . . 77 Comdis for eU-Consortia (GeR) . . . . . . . . . . . . . . . . . . . 84 Covestro deutschland aG. . . . . . . . . . . . . . . . . . . . . . . . 41 Curetis n.V. (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Cytosorbents (USa). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Cytune pharma SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 78 deCHema ausstellungs-GmbH (GeR) . . . . . . . . . . . . . . 37 dia europe (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 dionex aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 drooms GmbH (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . 85 earlybird Venture Capital (GeR) . . . . . . . . . . . . . . . . . . . 74 editas medicine (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . 76 eisai europe Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . 18, 23 eli Lilly (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 epidarex Capital (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . 79 epirus Biopharmaceuticals (USa) . . . . . . . . . . . . . . . . . . 78 eppendorf aG - Bioprocess Center europe (GeR) . . . . . . . 7 europaBio /european Biotech Week (B) . . . . . . . . . . . . . 29 european Biotechnology network (B) . . . . . . . . . . . . . . . 31 exosome diagnostics GmbH (GeR) . . . . . . . . . . . . . . . . 84 exosomics Siena (iT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84 exovita Bioscience (USa) . . . . . . . . . . . . . . . . . . . . . . . . 82 expedeon protein Solutions (UK) . . . . . . . . . . . . . . . . . . 72 Ferring international Center Sa (CH) . . . . . . . . . . . . . . . . 20 FGK Clinical Research GmbH (GeR) . . . . . . . . . . . . . . . 62 Finox Biotech aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . 78 Fresenius medical Care (GeR) . . . . . . . . . . . . . . . . . . . . . 83 FUJiFiLm diosynth Biotechnologies (USa) . . . . . . . . . . . 55 Galvani Bioelectronics (UK) . . . . . . . . . . . . . . . . . . . . . . 44 Gamamabs pharma S.a. (F) . . . . . . . . . . . . . . . . . . . . . . 27 Gedeon Richter Ltd. (HUn) . . . . . . . . . . . . . . . . . . . 78, 79 Generali deutschland Holding aG . . . . . . . . . . . . . . . . . 74 Genmab a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 Genomix4Life (iT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 GenSight Biologics (F) . . . . . . . . . . . . . . . . . . . . . . . . . . 70 Gilead Ltd. (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 GlaxoSmithKline (UK) . . . . . . . . . . . . . . . . . . . . . . . 23, 44 Global Bioenergies Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . 41 Glycemicon aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Gna Biosolutions GmbH (GeR) . . . . . . . . . . . . . . . . . . . 44 Gyros aB (Se) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Hansa medical aB (Se) . . . . . . . . . . . . . . . . . . . . . . . . . . 69

Health industries South australia (aUS) . . . . . . . . . . . . Cp2 High-Tech Gründerfonds (GeR) . . . . . . . . . . . . . . . . . . . 83 Hologic diagnostics Solutions international (USa) . . . . . 44 HS Life Sciences (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . 71 iCoS Corporation (USa) . . . . . . . . . . . . . . . . . . . . . . . . . 18 igenomix (eS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 immago Biosystems Ltd (UK) . . . . . . . . . . . . . . . . . . . . . 69 immudex a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 immunoQure aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . 71 innovate UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 isomerase Therapeutics Ltd (UK) . . . . . . . . . . . . . . . . . . . 68 Janssen Biologics B.V. (nL) . . . . . . . . . . . . . . . . . . . . . . . 68 Kadmon pharmaceuticals (USa) . . . . . . . . . . . . . . . . . . . 44 Lek d.d. (Si) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 Leo pharma a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 Life Science austria LiSa (aT) . . . . . . . . . . . . . . . . . . . . . 75 Luminex (iT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 m+W Central europe GmbH (GeR) . . . . . . . . . . . . . . . . 61 malvern (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 merck & Co. (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 merck KGaa (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 merck millipore (USa) . . . . . . . . . . . . . . . . . . . . . . . . . . 73 merigen Research srl. . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 miacom diagnostics GmbH (GeR) . . . . . . . . . . . . . . . . . 19 midiagnostics (USa/B) . . . . . . . . . . . . . . . . . . . . . . . . . . 44 mLm medical Labs GmbH (GeR) . . . . . . . . . . . . . . . . . . . 9 molzym GmbH & Co. KG (GeR) . . . . . . . . . . . . . . . . . . 19 neste Jacobs oy (Fi) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68 nodthera Ltd (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 nordic nanovector aS (n) . . . . . . . . . . . . . . . . . . . . . . . 69 norgine B.V. (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 nostrum Biodiscovery (eS) . . . . . . . . . . . . . . . . . . . . . . . 77 nova-institut GmbH (GeR) . . . . . . . . . . . . . . . . . . . . . . . 43 novartis aG (CH) . . . . . . . . . . . . . . . . . . . . . 24, 26, 68, 76 novo nordisk a/S (dK) . . . . . . . . . . . . . . . . . . . . . . . 26, 68 nRW.Bank (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 octapharma aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . 26 ono pharmaceutical Co. Ltd (Jp) . . . . . . . . . . . . . . . . . . 70 opiS s.r.l. (iT) . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 62, 64 oribase (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 oxitec Ltd. (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 packard Biosciences (UK) . . . . . . . . . . . . . . . . . . . . . . . . 44 particle metrix (GeR). . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 perkin elmer (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Pfizer (USA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 74 Pfizer CentreOne (USA) . . . . . . . . . . . . . . . . . . . . . . . . Cp4 pharmamar S.a. (eS) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 pharmathen S.a. (GR) . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 pharnext SaS (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70 plasmidFactory GmbH & Co.KG (GeR) . . . . . . . . . . . 57, 60 polpharma biologics (pL) . . . . . . . . . . . . . . . . . . . . . 59, 78 proBioGen aG (GeR) . . . . . . . . . . . . . . . . . . . . . 63, 66, 67 proteogenix Sa (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Qiagen nV (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Recordati S.p.a. (iT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Rentschler Biotechnologie GmbH (GeR) . . . . . . . . . . . . . 53 Richter-Helm BioLogics GmbH & Co. KG (GeR). . . . . . . 46 Roche aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19, 25 Rodos BioTarget GmbH (GeR) . . . . . . . . . . . . . . . . . . . . 74 Roquette Group (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72 Samsung (Korea) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Sandoz aG (CH) . . . . . . . . . . . . . . . . . . . . . . . . . 26, 76, 77 Selvita sp. z o.o. (pL) . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 Sotio a.s. (CR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78 Spectral medical (USa). . . . . . . . . . . . . . . . . . . . . . . . . . 22 SphingoTec GmbH (GeR) . . . . . . . . . . . . . . . . . . 17, 86, 87 SpiroChem (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 SR-Tiget (iT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 STaT diagnostica & innovation (eS) . . . . . . . . . . . . . . . . 19 Swedish orphan Biovitrum (Se) . . . . . . . . . . . . . . . . 26, 27 Swiss Biotech association (CH). . . . . . . . . . . . . . . . . . . Cp3 SyGniS pharma aG (GeR) . . . . . . . . . . . . . . . . . . . . . . . 72 Takeda pharmaceuticals (Jp) . . . . . . . . . . . . . . . . . . . . . . 18 Targovax aS (n) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 TauRx Therapeutics (UK) . . . . . . . . . . . . . . . . . . . . . . 27, 79 Teva pharmaceutical industries Ltd. (iL) . . . . . . . . . . . . . 23 ThermoFisher Scientific (USA) . . . . . . . . . . . . . . . . . 18, 44 ThromboGenics nV (B) . . . . . . . . . . . . . . . . . . . . . . . . . 26 TxCell S.a. (F). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 Unicyte (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 uniQure BV (nL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Valeant pharmaceuticals inc. (Cdn) . . . . . . . . . . . . . . . . 71 Valneva Se (F) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Vetter pharma-Fertigung GmbH & Co.KG (GeR) . . . . . . . 25 Videregen Ltd (UK) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Viomedo (GeR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 VTU Technology GmbH (aT) . . . . . . . . . . . . . . . . . . 50, 67 xigen pharma Sa (CH) . . . . . . . . . . . . . . . . . . . . . . . . . . 36 ZaB Brandenburg economic development Board (GeR) 13 ZHaW - Zurich University of applied Sciences (CH) . . . 64

Knack to seal Candor BIoSCIEnCE Liquid plate

Sealer® animal-free is a coating stabiliser without animal-derived ingredients for antibodies and antigens coated on polystyrene or glass-surfaces. after immobilisation of the antibodies or antigens and blocking, Liquid plate Sealer seals the plates with a uniform stabilising layer, demonstrating good solubility and without affecting the assay afterwards. Liquid plate Sealer can be used for stabilising coated eLiSa plates, immunochromatographicy test strips (lateral flow assays), affinity chromatography columns, protein arrays and for similar applications. due to the fact that Liquid plate Sealer animal-free does not contain animal-

derived ingredients it is a suitable coating stabiliser for veterinary diagnostics. Liquid plate Sealer animal-free is readyto-use and available in bottle sizes of 50 ml, 125 ml and 500 ml. it is applicable for research kits and for commercial eLiSa kit production. ContaCt

Candor Bioscience GmbH tel.: +49 (0)7522 7952 70 Fax: +49 (0)7522 7952 729 info@candor-bioscience.de www.candor-bioscience.com

SAVE THE DATE

SWISS BIOTECH DAY 2017

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association

In 2017, this premier event will once again offer a high quality conference programme and dedicated one-to-one partnering opportunities. So save the date and become part of CLUSTER the constantly growing Swiss Biotech Day next spring.

roject-specific m young and inehensive partner blic window. s are important e Biotech secerstanding of the brought into sociation, where

Alexakis ve Director ss Biotech

Pre-register online at www.swissbiotechday.ch to be one of the first to receive all information on programme, exhibitors and the partnering system as soon as it is available.

Picture: © Rynacher/ https://commons.wikimedia.org/wiki/File:Basilisk_ Wettsteinbrücke.JPG (CC BY-SA 3.0); GNU Free Documentation License

Mark your calendar for next year’s Swiss Biotech Day, the leading biotechnology conference in Switzerland. Don’t miss the chance to meet 500 senior experts from industry and academia in the life science sector from across Europe.

APRIL 2013 4 MAY9,2017 SIX Swiss Exchange, Basel Congress Center ConventionPoint, Zurich

SWISS BIOTECH...

...is an alliance of four leading Biotech regions of Switzerland (Bio Alps, BioPolo Ticino, Basel Area Sponsors: and Greater Zurich Area). They have combined efforts to streamline interests of the national biotech sector. The SWX Swiss Exchange holds a leading position in terms of lifescience listings and offers companies from that industry – be they located in Switzerland or abroad – access to an internationally recognised financial marketplace. The initiative was co-founded by the SBA which also manages the executive office Organised by:of Swiss Biotech.

For further information please visit www.swissbiotechassociation.ch

In cooperation with:

Supporting Partners:

Media Partner:

Bringing together the best of

When it’s

YOUR

compound, every step matters.

www.pﬁzercentreone.com API